Glutamate and psychiatric disorders
- 1 May 2002
- journal article
- Published by Cambridge University Press (CUP) in Advances in Psychiatric Treatment
- Vol. 8 (3) , 189-197
- https://doi.org/10.1192/apt.8.3.189
Abstract
Most of the excitatory neurotransmission in the central nervous system (CNS) is mediated by the endogenous excitatory amino acids (EAAs) glutamate, aspartate and homocysteine. Most of the endogenous inhibitory neurotransmission is mediated by gamma-aminobutyric acid (GABA). EAAs modulate the firing of almost all neurons in the CNS, as excitatory neurotransmission can result in both neuronal inhibition and excitation. The glutamate system is the best characterised of the EAA systems (Box 1).Keywords
This publication has 40 references indexed in Scilit:
- Serotonin model of schizophrenia: emerging role of glutamate mechanismsBrain Research Reviews, 2000
- Interactive effects of subanesthetic ketamine and haloperidol in healthy humansPsychopharmacology, 1999
- A Double-Blind Placebo-Controlled Study of Lamotrigine Monotherapy in Outpatients With Bipolar I DepressionThe Journal of Clinical Psychiatry, 1999
- Serotonergic Agents That Activate 5HT2A Receptors Prevent NMDA Antagonist NeurotoxicityNeuropsychopharmacology, 1998
- Neurotransmitter aberrations in schizophrenia: New perspectives and therapeutic implicationsLife Sciences, 1997
- Symptoms of SchizophreniaArchives of General Psychiatry, 1995
- Safety and Tolerability of the Glutamate Antagonist CGS 19755 (Selfotel) in Patients With Acute Ischemic StrokeStroke, 1995
- Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in HumansArchives of General Psychiatry, 1994
- Neurotransmission in the rat amygdala related to fear and anxietyTrends in Neurosciences, 1994
- Recent advances in the phencyclidine model of schizophreniaAmerican Journal of Psychiatry, 1991